This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MacGowan, A. P.
Right arrow Articles by Reeves, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MacGowan, A. P.
Right arrow Articles by Reeves, D. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1998, p. 419-424, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro Activities of Y-688, a New 7-Substituted Fluoroquinolone, against Anaerobic Bacteria

A. P. MacGowan,* K. E. Bowker, M. Wootton, H. A. Holt, and D. S. Reeves

Bristol Centre for Antimicrobial Research and Evaluation, Southmead Health Services NHS Trust and University of Bristol, Department of Medical Microbiology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, United Kingdom

Received 23 July 1997/Returned for modification 20 September 1997/Accepted 20 November 1997

The in vitro activities of Y-688, a new 7-substituted fluoroquinolone derivative, against 317 nonduplicate anaerobic isolates were determined. Eighty-five percent of the Bacteroides fragilis group (n = 89) were inhibited by <= 2 mg of Y-688 per liter, while 78, 100, 89, and 98% of gram-negative bacilli (n = 135), gram-positive cocci (n = 59), and non-spore-forming (n = 58) and spore-forming (n = 51) gram-positive bacilli, respectively, were inhibited by <= 1 mg of Y-688 per liter.


* Corresponding author. Mailing address: Department of Medical Microbiology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, United Kingdom. Phone: 0044 117 959 5652. Fax: 0044 117 959 3154. E-mail: STAFF{at}BCARE.ORG.UK.


Antimicrobial Agents and Chemotherapy, February 1998, p. 419-424, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Doi, Y., Shibata, N., Shibayama, K., Kamachi, K., Kurokawa, H., Yokoyama, K., Yagi, T., Arakawa, Y. (2002). Characterization of a Novel Plasmid-Mediated Cephalosporinase (CMY-9) and Its Genetic Environment in an Escherichia coli Clinical Isolate. Antimicrob. Agents Chemother. 46: 2427-2434 [Abstract] [Full Text]